a1c semaglutide Oral "ozempic" lowers and body weight in patients with type 2 diabetes Off-label semaglutide, tirzepatide lower HbA1c,

The American Diabetes Association (ADA) Standards of Care recommend specific GLP-1 receptor agonists with proven cardiovascular benefit (injectable semaglutide, liraglutide, and dulaglutide) for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high cardiovascular risk

Cons: Digestive Issues: Can cause bloating or discomfort in individuals with lactose intolerance

The damage caused by SAP to the vascular endothelium is manifested as the release of inflammatory mediators and leukocyte adhesion, increased vascular permeability, changes in blood flow shear stress, microthrombosis, and microcirculatory disorders

Recovery times can vary